ASCO GU 2023 Conference Coverage

 

ASCO GU 2023 Conference Coverage
Avatar

ASCO GU 2023 JAVELIN Bladder 100 Trial: Avelumab 1L Maintenance for Advanced Urothelial Carcinoma - Long-Term Follow-Up in Subgroups Defined by 1L Chemo Regimen & Analysis of OS From Start of 1L Chemo

By ASCO GU 2023 Conference Coverage FEATURING Kala Sridhar
By ASCO GU 2023 Conference Coverage FEATURING Kala Sridhar
250 views
March 8, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

19:22
Janssen Oncology

Doc Talk Podcast

Feat. J. Hamilton, M. Fabrizio, M. Taha

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Videos
07:52
ASCO GU 2023 Conference Coverage

Independent Biomarkers Predictive of Outcomes With Enfortumab Vedoti…

Feat. T. Jindal
06:49
ASCO GU 2023 Conference Coverage

ASCO GU 2023 DEAR Study: Real-World Use of Darolutamide, Enzalutamid…

Feat. D. George
12:39
ASCO GU 2023 Conference Coverage

Efficacy and Safety of Darolutamide in Combination With ADT and Doce…

Feat. C. Sternberg
08:18
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Effectiveness of Darolutamide in mCRPC

Feat. A. Liang
05:39
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Analysis of the UNITE Study: Biomarkers of Response to …

Feat. T. Jindal
11:07
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Innovative and Pragmatic Methods to Study BCG-Unrespons…

Feat. J. Gore
07:09
ASCO GU 2023 Conference Coverage

ASCO GU 2023 HER2 Expression in Urothelial Carcinoma

Feat. V. Koshkin
07:23
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Response & Outcomes of Maintenance Avelumab After P…

Feat. P. Grivas, D. Bakaloudi
10:44
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Additional Results From the Randomized Phase 2 CheckMat…

Feat. R. Pachynski
07:06
ASCO GU 2023 Conference Coverage

ASCO GU 2023 JAVELIN Bladder 100 Trial: Avelumab 1L Maintenance for …

Feat. K. Sridhar
05:40
ASCO GU 2023 Conference Coverage

ASCO GU 2023 International Phase 3 Randomised Controlled PACE-A Tria…

Feat. N. van As
08:32
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Assessment of AR-LBD Mutations in mCRPC

Feat. E. Antonarakis
07:36
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Assessment of Clavien-Dindo Classification in Patients …

Feat. K. Runcie
05:31
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase I/II AlphaBet Trial: Evaluating the Combination o…

Feat. A. Azad
04:34
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase I/II LuCAB Trial: Evaluating Cabazitaxel in Combi…

Feat. A. Azad
05:20
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Efficacy of Systemic Therapy Following [177Lu]Lu-PSMA i…

Feat. A. Azad
03:05
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Adjuvant Therapies in Renal Cell Carcinoma: Are New Dat…

Feat. M. Zibelman
05:47
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Outcomes by IMDC Risk in the COSMIC-313 Phase 3 Trial: …

Feat. T. Powles
07:03
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Evidence From Four High-Volume Institutions:…

Feat. O. Caffo
10:24
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Data from an Italian Multicenter Observation…

Feat. O. Caffo
07:49
ASCO GU 2023 Conference Coverage

ASCO GU 2023 First Analysis From an Italian Multicenter Observationa…

Feat. O. Caffo
12:48
ASCO GU 2023 Conference Coverage

Cost-Effectiveness Analysis of Seven Treatment Regimens in mHSPC: A …

Feat. M. Kohli
07:53
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase 3 IMvigor130 Study: Final OS Analysis of Atezo Mo…

Feat. A. Bamias
13:01
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Interim Analysis of the Prospective Phase II COTRIMS Tr…

Feat. A. Heidenreich
09:47
ASCO GU 2023 Conference Coverage

FDA Announcement Based on the MAGNITUDE Trial: Niraparib With Abirat…

Feat. E. Efstathiou
01:46
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blind Phase 3 KEYNOTE-921 Study: Pemb…

Feat. D. Petrylak
08:45
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Machine-Learning to Predict Utility of ctDNA for Somati…

Feat. C. Herberts
04:49
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Updated Outcomes in TROPHY-U-01 Cohort 1-A Phase 2 Stud…

Feat. S. Tagawa
05:48
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blinded Phase II Study of Keto HC and…

Feat. S. Tagawa
14:09
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Exposure Toxicity and Response Relationship of Cabozant…

Feat. Y. Vano
04:20
ASCO GU 2023 Conference Coverage

ASCO GU 2023 CaboPoint Phase 2 Study: Cabozantinib After Checkpoint …

Feat. L. Albiges
05:32
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Cell-Free utDNA to Detect MRD Prior to Repeat-Transuret…

Feat. K. Rose
14:01
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Pro…

Feat. A. D'Amico
12:05
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Novel Guidelines for PSMA PET Staging of Prostate Cance…

Feat. D. Nanus
12:01
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Sequential Enfortumab Vedotin After Platinum-Based Chem…

Feat. P. Cen
08:15
ASCO GU 2023 Conference Coverage

ASCO GU 2023 3-Year Follow-Up From The Phase 3 CheckMate 9ER Trial: …

Feat. M. Burotto
15:17
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Systemic Therapy for Recurrent Metastatic RCC: Beyond S…

Feat. T. Zhang
02:42
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Day Three Highlights With Resident Jindal and Dr. Park

Feat. T. Jindal, C. Park
22:25
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Prostate and Bladder Updates With Dr. Jones and Dr. Park

Feat. R. Jones, C. Park
09:22
ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Park and Dr. Grivas Discuss TROPHY-U-01 and EV-201…

Feat. P. Grivas, C. Park
08:13
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Dr. Plimack and Dr. Park Discuss Over-Treating in Muscl…

Feat. E. Plimack, C. Park
08:59
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Treatment Outcomes With New Targeted Agents in Advanced…

Feat. V. Koshkin, C. Park
06:04
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase II Study Rucaparib Monotherapy in Pts With nmHSPC…

Feat. K. Sahu, C. Park
06:34
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Dr. Flaig and Dr. Park Discuss Updates in Prostate and …

Feat. T. Flaig, C. Park
05:18
ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Miron and Dr. Park Discuss Kidney and Bladder Upda…

Feat. B. Miron, C. Park
06:19
ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Park and Dr. Gupta Discuss the BLASST-1 Study

Feat. S. Gupta, C. Park
09:12
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Longitudinal Detection of ctDNA in Patients With Advanc…

Feat. A. Basu, C. Park
03:08
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Day Two Highlights With Dr. Talukder and Dr. Park

Feat. R. Talukder, C. Park
10:32
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Dr. Rettig and Dr. Park Discuss Prostate Cancer Updates

Feat. M. Rettig, C. Park
05:57
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Comparison of ctDNA Between African-American and Caucas…

Feat. A. Jang, C. Park
10:01
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Bladder Cancer Highlights With Dr. Sonpavde and Dr. Park

Feat. G. Sonpavde, C. Park
01:53
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Day One Highlights With Dr. Zakharia

Feat. Y. Zakharia